# Fairooz F. Kabbinavar

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/fairooz-f-kabbinavar/

## Facts

| Field | Value |
| --- | --- |
| Citations | 37,886 |
| Field | Renal cell carcinoma treatment |
| h-index | 64 |
| i10-index | 133 |
| OpenAlex ID | https://openalex.org/A5006496749 |
| ORCID iD | https://orcid.org/0009-0003-2552-4935 |
| Works | 263 |

## Researcher papers

- [Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial](https://scholariq.org/papers/atezolizumab-versus-docetaxel-in-patients-with-previously-treated-non-small-cell/)
- [First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer](https://scholariq.org/papers/first-line-atezolizumab-plus-chemotherapy-in-extensive-stage-small-cell-lung/)

## Researcher topics

- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Renal and related cancers](https://scholariq.org/topics/renal-and-related-cancers/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.